SOS1 inhibitor (Acerand Therapeutics)

This SOS1 inhibitor is a small molecule therapeutic being developed by Acerand Therapeutics for the treatment of solid tumors. It specifically targets Son of Sevenless homolog 1 (SOS1), a guanine nucleotide exchange factor (GEF) that plays a critical role in the activation of RAS proteins. By binding to SOS1, the inhibitor prevents the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on RAS, thereby maintaining RAS in its inactive state and blocking downstream oncogenic signaling through the MAPK/ERK pathway. This mechanism is designed to address cancers driven by various RAS mutations, including KRAS G12D, either as a monotherapy or in combination with direct RAS inhibitors to overcome resistance. The drug is currently in the IND-enabling phase of development.

Other names

Acerand SOS1 inhibitor